|Videos|October 7, 2021
Dr. Stewart discusses study of neoadjuvant axitinib in renal cell carcinoma
Author(s)Urology Times staff
“The concept behind the NAXIVA trial was to treat these patients with pre-surgical neoadjuvant targeted therapy with a means of downstaging that venous tumor thrombus, reducing the extent of it to try and make the surgery less morbid to the patient and to potentially improve survival,” says Grant Stewart, MD.
Advertisement
In this video, Grant Stewart, MD, discusses the background and findings of the study, “NAXIVA – a phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer with venous invasion: translational results.” Stewart is a professor of surgical oncology and honorary consultant urological surgeon at the University of Cambridge, England, United Kingdom.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
